Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus ATRACURIUM BESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus ATRACURIUM BESYLATE.
ARDUAN vs ATRACURIUM BESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and causing skeletal muscle relaxation.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
0.4–0.5 mg/kg IV bolus for intubation; maintenance: 0.08–0.1 mg/kg IV as needed or infusion 5–10 mcg/kg/min
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Clinical Note
moderateAtracurium besylate + Tranilast
"Atracurium besylate may increase the neuromuscular blocking activities of Tranilast."
Clinical Note
moderateAtracurium besylate + Tolfenamic acid
"Atracurium besylate may increase the neuromuscular blocking activities of Tolfenamic acid."
Clinical Note
moderateAtracurium besylate + Nimesulide
"Atracurium besylate may increase the neuromuscular blocking activities of Nimesulide."
Clinical Note
moderateAtracurium besylate + Risedronic acid
Terminal elimination half-life is approximately 20 minutes (range 15-25 min) in healthy adults. Clinical context: Recovery from neuromuscular blockade is faster than for nondepolarizing relaxants cleared renally. Half-life may be prolonged in hypothermia or acidosis but is minimally affected by renal or hepatic impairment.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Renal (50-60% unchanged), biliary/fecal (20-30% as metabolites, mainly laudanosine), and Hofmann elimination (non-enzymatic, pH- and temperature-dependent) accounts for approximately 40-50% of clearance.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker
"Atracurium besylate may increase the neuromuscular blocking activities of Risedronic acid."